These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 16735371

  • 1. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
    Byun JH, Lee MA, Roh SY, Shim BY, Hong SH, Ko YH, Ko SJ, Woo IS, Kang JH, Hong YS, Lee KS, Lee AW, Park GS, Lee KY.
    Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
    [Abstract] [Full Text] [Related]

  • 2. [Effect of cyclooxygenase-2,and matrix metalloproteinase-2 expression on prognosis of lung cancer].
    Zhang HZ, Lu ZQ, Xie DR, Li HG, Xiong LH, Zhang H, Chen XB.
    Ai Zheng; 2004 Oct; 23(10):1190-3. PubMed ID: 15473933
    [Abstract] [Full Text] [Related]

  • 3. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
    Li L, Mei TH, Zhou XD, Zhang XG.
    Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
    [Abstract] [Full Text] [Related]

  • 4. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.
    Cancer; 2005 Apr 15; 103(8):1676-84. PubMed ID: 15754326
    [Abstract] [Full Text] [Related]

  • 5. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
    Hsu CP, Shen GH, Ko JL.
    Lung Cancer; 2006 Jun 15; 52(3):349-57. PubMed ID: 16569461
    [Abstract] [Full Text] [Related]

  • 6. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
    Kim SH, Choi HY, Lee J, Son DS, Lee HS, Song IS, Lim YS, Hong YS, Kim J, Choi YS.
    J Surg Oncol; 2007 Mar 15; 95(4):337-46. PubMed ID: 17326127
    [Abstract] [Full Text] [Related]

  • 7. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.
    Cancer Lett; 2006 May 08; 236(1):125-32. PubMed ID: 15982804
    [Abstract] [Full Text] [Related]

  • 8. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, Baba M, Shiba M.
    Clin Cancer Res; 1999 Jan 08; 5(1):149-53. PubMed ID: 9918213
    [Abstract] [Full Text] [Related]

  • 9. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].
    Zhang HZ, Wei YP, Li HG, Wang M, Liu JG, Wu C.
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep 08; 26(9):1307-10. PubMed ID: 16982442
    [Abstract] [Full Text] [Related]

  • 10. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
    Passlick B, Sienel W, Seen-Hibler R, Wöckel W, Thetter O, Mutschler W, Pantel K.
    Clin Cancer Res; 2000 Oct 08; 6(10):3944-8. PubMed ID: 11051242
    [Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
    Milas I, Komaki R, Hachiya T, Bubb RS, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L.
    Clin Cancer Res; 2003 Mar 08; 9(3):1070-6. PubMed ID: 12631609
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Correlation of matrix metalloproteinase-3 polymorphism to genetic susceptibility and lymph node metastasis of non-small cell lung cancer].
    Fang SM, Jin X, Li Y, Wang R, Guo W, Wang N, Zhang JH.
    Ai Zheng; 2005 Mar 08; 24(3):305-10. PubMed ID: 15757531
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
    Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y, Mo M, He J.
    J Surg Oncol; 2011 Dec 08; 104(7):841-6. PubMed ID: 21721010
    [Abstract] [Full Text] [Related]

  • 20. [Expression of COX-2 and MMP-9 in cervical carcinoma and their clinical significance].
    Luo CF, Zhu RQ, Wang H, Lu YL.
    Zhonghua Zhong Liu Za Zhi; 2007 Jul 08; 29(7):526-30. PubMed ID: 18069634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.